ChiCTR2100050814 版本V1.6 版本创建时间2022/04/30 11:54:44 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100050814 

最近更新日期:

Date of Last Refreshed on:

2022-04-04 20:58:00 

注册时间:

Date of Registration:

2021-09-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请填写伦理委员会联系人 胎儿肺动脉超声对新生儿呼吸窘迫综合征的预测价值

Public title:

The predictive value of fetal pulmonary ultrasonography for neonatal respiratory distress syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胎儿肺动脉超声对新生儿呼吸窘迫综合征的预测价值

Scientific title:

The predictive value of fetal pulmonary ultrasonography for neonatal respiratory distress syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周小凤 

研究负责人:

高淑强 

Applicant:

Zhou Xiaofeng 

Study leader:

Gao Shuqiang 

申请注册联系人电话:

Applicant telephone:

+86 18875034891

研究负责人电话:

Study leader's telephone:

+86 13881828130

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

805369839@qq.com

研究负责人电子邮件:

Study leader's E-mail:

gaoshuqiangww@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市青羊区日月大道1617号

研究负责人通讯地址:

四川省成都市青羊区日月大道1617号

Applicant address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan

Study leader's address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都市妇女儿童中心医院

Applicant's institution:

Chengdu Women's and Children's Central Hospital

研究负责人所在单位:

成都市妇女儿童中心医院

Affiliation of the Leader:

Chengdu Women's and Children's Central Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021(39)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都市妇女儿童中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chengdu Women's and Children's Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-05-28 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

四川省成都市青羊区日月大道1617号

Contact Address of the ethic committee:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都市妇女儿童中心医院

Primary sponsor:

Chengdu Women's and Children's Central Hospital

研究实施负责(组长)单位地址:

四川省成都市青羊区日月大道1617号

Primary sponsor's address:

1617 Riyue Avenue, Qingyang District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都市妇女儿童中心医院

具体地址:

青羊区日月大道1617号

Institution
hospital:

Chengdu Women's and Children's Central Hospital

Address:

1617 Riyue Avenue, Qingyang District

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

Target disease:

Pulmonary disease of neonates

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

建立正常胎儿肺超声肺动脉测值数据库,探索胎儿肺动脉超声对NRDS的预测价值。  

Objectives of Study:

To establish a database of ultrasonic pulmonary artery measurements in normal fetal lung, and to explore the predictive value of fetal pulmonary ultrasonography for NRDS.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 参试者知情同意;
2. 单胎,孕龄确切,早期超声检查胎儿发育与孕周相符;
3. 多普勒测量前无见红、宫缩等临产征兆;
4. 多普勒测量前未使用糖皮质激素。

Inclusion criteria

1. Informed consent of participants;
2. Single fetus with exact gestational age, early ultrasound examination of fetal development consistent with gestational age;
3. There were no signs of labor such as redness or contractions before Doppler measurement;
4. Glucocorticoids were not used before Doppler measurement.

排除标准:

1. 未定期产前检查或母儿数据资料不完整;
2. 胎儿存在发育异常和畸形;
3. 小于胎龄儿或大于胎龄儿;
4. 急产无法完成肺动脉超声检查者。

Exclusion criteria:

1. The puerpera did not have regular prenatal examination or the data of mother and infant could not be obtained;
2. Abnormal development and malformation of the fetus;
3. Small or large for gestational age;
4. Patients with acute labor who cannot complete pulmonary ultrasonography.

研究实施时间:

Study execute time:

From 2021-12-01 00:00:00 To 2023-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-12-01 00:00:00 To 2023-06-01 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

临床症状、体征以及肺部X光。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Clinical symptoms,signs and lung X-ray.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

胎儿产前肺超声。

Index test:

Prenatal fetal lung ultrasound.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

胎儿、新生儿。

例数:

Sample size:

1100

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Fetus and neonates.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

No

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

成都市妇女儿童中心医院 

单位级别:

三级甲等 

Institution
hospital:

Chengdu Women's and Children's Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

主肺动脉内径

指标类型:

主要指标

Outcome:

Inner diameter of the main pulmonary artery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉加速时间

指标类型:

次要指标

Outcome:

Acceleration time of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉射血时间

指标类型:

次要指标

Outcome:

Ejection time of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉收缩期加速时间(AT)/射血时间(ET)比值

指标类型:

次要指标

Outcome:

Accelerated systolic time/ejection time (AT/ET) rate of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉收缩期峰值流速

指标类型:

次要指标

Outcome:

Peak systolic velocity of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉舒张末期流速

指标类型:

次要指标

Outcome:

End-diastolic velocity of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉平均血流速度

指标类型:

次要指标

Outcome:

Average velocity of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉搏动指数

指标类型:

次要指标

Outcome:

Pulsatility index of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主肺动脉阻力指数

指标类型:

次要指标

Outcome:

Resistance index of main pulmonary artery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

左右肺动脉内径

指标类型:

主要指标

Outcome:

Inner diameter of left and right pulmonary artery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC, AUC of ROC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, AUC of ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Nil

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

共享通过Resman平台或成都市妇女儿童中心医院科教科。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Through Resman platform or Department of Science and education of Chengdu Women's and Children's Center Hospital.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表或EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form or EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-09-04 21:19:24